Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Financial writer recommends Voyager Therapeutics, Inc. for high-risk investors due to promising preclinical Alzheimer's ...

BIIB's regulatory filings are supported by late-stage data, which show that treatment with a higher Spinraza dose improves motor function in infants with SMA.

FDA-approved ALS treatments available in the U.S. include Mitsubishi Tanabe's Radicava, generic drug riluzole, and Biogen's (BIIB.O), opens new tab Qalsody. Sign up here. Reporting by Puyaan Singh ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...

The drug will launch within a week, it said, with no news yet on pricing, although Biogen did tell Reuters it would be in line with other recently launched ALS treatments and out-of-pocket costs ...

and generic drug riluzole (sold as Rilutek by Sanofi), and Biogen's Qalsody (tofersen), the latter only if they have a genetic form of ALS associated with a mutation in the SOD1 gene. President ...

Private Medicare plans must cover Biogen's ALS drug, US agency says Healthcare & Pharmaceuticalscategory· December 13, 2024 Corcept Therapeutics said on Wednesday its experimental drug failed to ...

The U.S. Food and Drug Administration (FDA) recently issued two new guidance documents governing details of the Accelerated Approval ...

Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...